Outlook Therapeutics submits CMS application for permanent J-code for LYTENAVA

Bitget2026/10/01 13:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Outlook Therapeutics filed an HCPCS Level II application with CMS seeking a permanent, product-specific J-code for LYTENAVA.
Move targets a clearer US reimbursement pathway ahead of the planned commercial launch before year-end 2026.
CMS review does not assure J-code assignment or guarantee coverage or payment by Medicare or commercial insurers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010901PRIMZONEFULLFEED9837882) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Outlook Therapeutics submits CMS application for permanent J-code for LYTENAVA

You may also like

Crypto prices